Showing results (111-120 of 366) with videos related to
Sort By:
Pageof 37
Lung Cancer (Amsterdam, Netherlands)|August 28, 2016
A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)Egbert F Smit, Yi-Long Wu, Radj Gervais, et al.Critical Reviews in Oncology/Hematology|April 28, 2025
Clinical trials for patients with salivary gland cancers: A systematic review of worldwide registers and an evaluation of current challengesPablo Jiménez-Labaig, Luigi Lorini, Cristina Gurizzan, et al.The New England Journal of Medicine|November 18, 2020
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung CancerAlice T Shaw, Todd M Bauer, Filippo de Marinis, et al.Plos One|January 30, 2013
Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patientsPablo Martinez, Javier Hernández-Losa, Ma Ángeles Montero, et al.Clinical Lung Cancer|May 12, 2026
ENTRÉE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLCMarina Chiara Garassino, Sophie Cousin, Benjamin Besse, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 7, 2014
An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancerGiorgio V Scagliotti, Enriqueta Felip, Benjamin Besse, et al.The Oncologist|December 26, 2022
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint InhibitorsFabrice Barlesi, Nicolas Isambert, Enriqueta Felip, et al.BMC Psychology|November 24, 2020
Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal studyN Nuria Viñolas, Rosario Garcia-Campelo, Margarita Majem, et al.The New England Journal of Medicine|December 4, 2014
First-line crizotinib versus chemotherapy in ALK-positive lung cancerBenjamin J Solomon, Tony Mok, Dong-Wan Kim, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 25, 2023
The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual SymposiumNuria Viñolas, Laura Mezquita, Jesús Corral, et al.Pageof 37